1-乙基-3-(4-甲基苯基)脲 | 84662-50-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 1-乙基-3-(4-甲基苯基)脲
• 英文名称: 1-ethyl-3-p-tolylurea
• 英文别名: 1-Ethyl-3-(4-methylphenyl)urea
• CAS: 84662-50-0
• 化学式: C₁₀H₁₄N₂O
• mdl: MFCD00089025
• 分子量: 178.234
• InChiKey: OOVXVHYLNJAOKN-UHFFFAOYSA-N

物化性质

• 熔点：
  97-98 °C
• 沸点：
  268.7±23.0 °C(Predicted)
• 密度：
  1.086±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  41.1
• 氢给体数：
  2
• 氢受体数：
  1

安全信息

• 海关编码：
  2924299090

反应信息

• 作为反应物：
  描述：

  1-乙基-3-(4-甲基苯基)脲 在 四(三苯基膦)钯 、 三乙胺 、 三苯基膦 、 二溴三苯基膦 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 反应 13.0h， 生成 4-ethenyl-N-ethyl-3-(4-methylphenyl)-1,3-oxazolidin-2-imine
  参考文献：
  名称：

  Highly Enantioselective Synthesis of 1,3-Oxazolidin-2-imine Derivatives by Asymmetric Cycloaddition Reactions of Vinyloxiranes with Unsymmetrical Carbodiimides Catalyzed by Palladium(0) Complexes

  摘要：

  4-Vinyl-1,3-oxazoilidin-2-imine derivatives have been synthesized by cycloaddition reactions of 2-vinyloxiranes with unsymmetrical carbodiimides catalyzed by palladium(0) complexes-in excellent total isolated yields. After reaction two compounds were always formed, one of which was isolated as the major product. A bulky alkyl group on one of the nitrogen atoms of the carbodiimide enhanced the product ratio in favor of the N-aryl-3-alkyl-1,3-oxazolidin-2-imine. Highly enantioselective cycloadducts (up to >99% ee) were formed by using TolBINAP as the chiral phosphine ligand, in THF at ambient temperatures. The enantiodetermination is believed to be dependent on nucleophilic attack of the anionic nitrogen of the carbodiimide due to the steric interaction of the carbodiimide substituents with the chiral phosphine ligand.

  DOI：

  10.1021/jo9804341
• 作为产物：
  描述：

  乙基(4-甲基苯基)碳二亚胺 在 水 作用下， 生成 1-乙基-3-(4-甲基苯基)脲
  参考文献：
  名称：

  Scherowsky, Guenther; Pickardt, Joachim, Chemische Berichte, 1983, vol. 116, # 1, p. 186 - 196

  摘要：

  DOI：

文献信息

• NOVEL 3,5-DISUBSTITUTED-3H-IMIDAZO[4,5-B]PYRIDINE AND 3,5- DISUBSTITUTED -3H-[1,2,3]TRIAZOLO[4,5-B] PYRIDINE COMPOUNDS AS MODULATORS OF C-MET PROTEIN, ETC
  申请人：Rhizen Pharmaceuticals SA

  公开号：US20150057309A1

  公开（公告）日：2015-02-26

  The present invention provides compounds useful as c-Met protein kinase modulators, methods of preparing them, pharmaceutical compositions containing them and methods of treatment, prevention and/or amelioration of c-Met kinase mediated disease or disorders with them.

  本发明提供了作为c-Met蛋白激酶调节剂有用的化合物，以及制备它们的方法，含有它们的药物组合物，以及使用它们进行治疗、预防和/或改善c-Met激酶介导的疾病或疾病的方法。
• Alkylation potency and protein specificity of aromatic urea derivatives and bioisosteres as potential irreversible antagonists of the colchicine-binding site
  作者：Jessica S. Fortin、Jacques Lacroix、Michel Desjardins、Alexandre Patenaude、Éric Petitclerc、René C.-Gaudreault

  DOI：10.1016/j.bmc.2007.04.028

  日期：2007.7

  antimitotics through their covalent binding to the colchicine-binding site on intracellular beta-tubulin. The present communication aimed to evaluate the role of the electrophilic 2-chloroethyl amino moiety of CEU on cell growth inhibition and the specificity of the drugs as irreversible antagonists of the colchicine-binding site. To that end, several N-phenyl-N'-(2-ethyl)urea (EU), N-phenyl-N'-(2-chloroethyl)urea

  已经显示出许多N-苯基-N'-（2-氯乙基）脲（CEU）通过与细胞内β-微管蛋白上秋水仙碱结合位点的共价结合而成为有效的抗有丝分裂剂。本交流旨在评估CEU的亲电2-氯乙基氨基部分对细胞生长的抑制作用以及作为秋水仙碱结合位点的不可逆拮抗剂的药物的特异性。为此，一些N-苯基-N'-（2-乙基）脲（EU），N-苯基-N'-（2-氯乙基）脲（CEU），N-芳基氨基-2-恶唑啉（OXA）制备了N-苯基-N'-（2-氯乙酰基）脲（CAU）衍生物，并测试了它们的抗增殖活性，对细胞周期的影响以及与β-微管蛋白的不可逆结合。欧盟衍生物缺乏抗增殖活性。CEU（2h-2i，2k，2l，OXA 3e，3h，3i，3k，3l，tBCEU和ICEU），OXA（3h，3i，3k，3l，tBOXA和IOXA）和CAU（4a-4m，tBCAU和ICAU）在三种肿瘤细胞系上的GI（50）在1.7和10microM之间。细胞毒
• NOVEL 3,5-DISUBSTITUTED-3H-IMIDAZO[4,5-B]PYRIDINE AND 3,5- DISUBSTITUTED -3H-[1,2,3]TRIAZOLO[4,5-B] PYRIDINE COMPOUNDS AS MODULATORS OF PROTEIN KINASES
  申请人：MUTHUPPALANIAPPAN Meyyappan

  公开号：US20110281865A1

  公开（公告）日：2011-11-17

  The present invention provides, inter alia, compounds of formula I as protein kinase modulators, methods of preparing them, pharmaceutical compositions containing them and methods of treatment, prevention and/or amelioration of kinase mediated diseases or disorders with them.

  本发明提供了一种公式I的化合物作为蛋白激酶调节剂，以及它们的制备方法、含有它们的药物组合物，以及利用它们治疗、预防和/或改善激酶介导的疾病或紊乱的方法。
• [EN] SPIROCYCLIC COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS AND DIAGNOSTIC PROBES<br/>[FR] COMPOSÉS SPIROCYCLIQUES ET LEUR UTILISATION COMME AGENTS THÉRAPEUTIQUES ET SONDES DE DIAGNOSTIC
  申请人：UNIV BASEL

  公开号：WO2011114275A1

  公开（公告）日：2011-09-22

  The invention relates to new triazines (G = Q = U are N), pyrimidines (two out of G, Q and U are N), and pyridopyrimidines (one of G and U together with R2 forms an anullated pyridine ring) of formula (I) carrying a spirocyclic substituent, wherein E1 is CR4 or N; X1 is CHR4, CH2CH2, NR4, NR4→0, or O; and the other substituents are as defined in the specification. The compounds inhibit phosphoinositide 3-kinase (PI3K), mammalian target of rapamycin (mTOR), DNA-PK and ATM kinase, and may be used as therapeutic agents or diagnostic probes. The invention also relates to methods of using the compounds for treatment of associated pathological conditions.

  本发明涉及新的三嗪类化合物（其中G = Q = U为N）、嘧啶类化合物（其中G、Q和U中的两个为N）和吡啶嘧啶类化合物（其中G和U中的一个与R2共同形成一个环状吡啶环），它们都带有一个螺环取代基，化学式为（I）。其中，E1为CR4或N；X1为CHR4、CH2CH2、NR4、NR4→0或O；其他取代基如规范中所定义。这些化合物能够抑制磷脂酰肌醇3-激酶（PI3K）、哺乳动物雷帕霉素靶蛋白酶（mTOR）、DNA-PK和ATM激酶，并可用作治疗剂或诊断探针。本发明还涉及使用这些化合物治疗相关病理条件的方法。
• Cu(II)-Catalyzed <i>Ortho</i>-C–H Nitration of Aryl Ureas By C–H Functionalization
  作者：Chun-Meng Wang、Kai-Xiang Tang、Tian-Hong Gao、Lin Chen、Li-Ping Sun

  DOI：10.1021/acs.joc.8b01016

  日期：2018.8.3

  A novel protocol for the aromatic ortho C–H nitration of aryl ureas with Fe(NO3)3·9H2O is developed. The reaction utilizes CuCl2·2H2O as catalyst and p-TSA as additive, showing good functional group tolerance and furnishing the desired products in moderate to excellent yields.

  提出了一种用Fe（NO 3）3 ·9H 2 O芳基尿素的芳族邻位碳氢硝化的新方案。该反应使用CuCl 2 ·2H 2 O作为催化剂，使用p -TSA作为添加剂，显示出良好的官能团耐受性，并以中等至极好的收率提供了所需的产物。